3,745 results match your criteria Borderline Ovarian Cancer


[Expression of ARID1A in ovarian seromucinous neoplasms and its clinicopathological significance].

Zhonghua Bing Li Xue Za Zhi 2020 Jun;49(6):588-593

Department of Pathology, the First Medical Center of PLA General Hospital, Beijing 100853, China.

To investigate the clinical, pathological and immunohistochemical features of seromucinous neoplasms, including seromucinous cystadenoma, borderline tumour and seromucinous carcinomas of the ovary. A retrospective review of the seromucinous neoplasms collected between June 2006 and December 2018 was conducted at the First Medical Center of PLA General Hospital. EnVision immunohistochemical staining was used to detect the expression of CK7, PAX8, ER, PR, WT1, p16, p53 and Baf250a which was encoded by the ARID1A gene. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3760/cma.j.cn112151-20200224-00130DOI Listing

Borderline serous ovarian neoplasm: case report of a diagnostic challenge in intraoperative frozen sections.

Case Rep Womens Health 2020 Jul 16;27:e00219. Epub 2020 May 16.

Department of Pathology, Tata Main Hospital, Jamshedpur, 831001, Jharkhand, India.

Surface epithelial tumors of the ovary account for 25% of all ovarian neoplasms. When composed predominantly of fibrous stroma, with glands and cysts forming a minor component, their appearance on imaging is often complex; cystic- to solid-appearing masses often raise suspicion of a malignant tumor. An accurate frozen histopathological diagnosis of a benign cystadenofibroma of this tumor can facilitate appropriate surgical management. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.crwh.2020.e00219DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7242860PMC

Laparoscopic Management of Giant Ovarian Cysts Using the Alexis Laparoscopic System®: A Case Series.

Front Surg 2020 6;7:24. Epub 2020 May 6.

Gynaecological Surgery Unit, Department of Women-Children-Teenagers, University Hospitals of Geneva, Geneva, Switzerland.

The aim of this study was to review the characteristics of patients who underwent laparoscopic removal of giant ovarian cysts using the Alexis Laparoscopic System® and confirm the safety and feasibility of this technique. We conducted a retrospective review of data of women undergoing the procedure from March 2014 to February 2019. Inclusion criteria were ovarian cysts of at least 15 cm. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fsurg.2020.00024DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7218052PMC

Ovarian carcinoma: pathology review with an emphasis in their molecular characteristics.

Chin Clin Oncol 2020 May 20. Epub 2020 May 20.

Surgical pathology, Instituto Nacional de Cancerología, Mexico City, Mexico.

Ovarian carcinoma is highly aggressive and difficult to treat neoplasm, which is usually detected in advanced stages where most patients recur. Extensive investigation about several treatment modalities has been performed but this neoplasm has poor benefits from such treatments including targeted therapy. Recent data have begun to highlight the histological and molecular heterogeneity of these tumors defining this neoplasm, not as a single disease but a group of heterogeneous histological subtypes with important differences in terms of genetics, morphology, oncogenesis, prognosis, chemosensitivity and especially molecular characteristics that are likely to be targets of new molecules. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/cco-20-31DOI Listing

Borderline ovarian tumours: management in the era of fertility-sparing surgery.

Ecancermedicalscience 2020 6;14:1031. Epub 2020 May 6.

Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Genova, Italy.

Borderline ovarian tumours (BOTs) are ovarian neoplasms characterised by epithelial proliferation, variable nuclear atypia and no evidence of destructive stromal invasion. BOTs account for approximately 15% of all epithelial ovarian cancers. Due to the fact that the majority of BOTs occur in women under 40 years of age, their surgical management often has to consider fertility-sparing approaches. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3332/ecancer.2020.1031DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7221127PMC

Expressions and clinical significances of STAT3 and Grim19 in epithelial ovarian cancer.

3 Biotech 2020 Jun 11;10(6):246. Epub 2020 May 11.

1Department of Gynaecology, Guangxi Medical University Affiliated Tumor Hospital, No. 71 Hedi Road, Nanning, 530021 China.

This study aimed to explore the expressions of signal transducer and activator of transcription 3 (STAT3) and a gene associated with retinoid-interferon induced mortality (Grim19) in epithelial ovarian cancer (EOC), and to determine their correlations with tumor progression and metastasis as well as the related mechanism. Ovarian tissue specimens resected through operation in our hospital were collected, and the correlations of Grim19 and STAT3 expressions with clinicopathological indexes were detected via immunohistochemistry (IHC) and Western blotting. Their positions in cells were observed through immunofluorescence. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13205-020-02237-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7214566PMC

Dataset on patients with Recurrent Borderline Ovarian Tumors and Table with Review of Literature on Fertility and Oncologic Outcomes of patients with Borderline Ovarian Tumors.

Data Brief 2020 Jun 30;30:105653. Epub 2020 Apr 30.

Department of Gynecology and Gynecologic Oncology, Ev. Kliniken Essen-Mitte, Essen, Germany.

The data presented here is related to the research article entitled "FERTILITY-SPARING SURGERY AND REPRODUCTIVE-OUTCOMES IN PATIENTS WITH BORDERLINE OVARIAN TUMORS" by Plett et al. in Journal of Gynecologic Oncology [1] and is analysed and discussed in detail. 18 Patients with Recurrent Borderline Ovarian Tumors (BOT) were identified and listed in Table 1. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.dib.2020.105653DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7206201PMC

SNCG promotes the progression and metastasis of high-grade serous ovarian cancer via targeting the PI3K/AKT signaling pathway.

J Exp Clin Cancer Res 2020 May 7;39(1):79. Epub 2020 May 7.

Department of Obstetrics and Gynecology, the First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.

Background: The poor prognosis of patients with ovarian cancer is mainly due to cancer progression. γ-Synuclein (SNCG) has reported as a critical player in cancer metastasis. However, its biological roles and mechanism are yet incompletely understood in ovarian cancer, especially in high-grade serous ovarian cancer (HGSOC). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13046-020-01589-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204046PMC

Psammoma bodies in Papanicolaou tests and associated factors to predict an underlying malignancy: a clinicopathological analysis of 10 cases.

J Am Soc Cytopathol 2020 Apr 11. Epub 2020 Apr 11.

Department of Pathology, University of Massachusetts Medical School-Baystate Medical Center, Springfield, Massachusetts.

Introduction: Psammoma bodies (PBs) are rarely encountered in Papanicolaou tests. They have been described in benign and malignant conditions of the gynecologic tract and peritoneum. The aim of our study was to reveal the associated factors with PBs in Papanicolaou tests to predict an underlying malignancy, particularly in the absence of atypical glandular cells (AGCs). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jasc.2020.04.002DOI Listing

A sporadic gastric-type endocervical adenocarcinoma with endometrial involvement and bilateral ovarian metastasis, a case report.

Gynecol Oncol Rep 2020 May 18;32:100572. Epub 2020 Apr 18.

Department of Gynecologic Oncology, MCC, United States.

•Gastric type endocervical adenocarcinoma (GAS) is rare in the United States.•GAS is an aggressive tumor and can metastasize unusual sites including peritoneal surfaces and adnexa.•Metastatic lesions can mimic benign/borderline mucinous tumors of ovaries. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.gore.2020.100572DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7182719PMC

The generally low sensitivity of CA 125 for FIGO stage I ovarian cancer diagnosis increases for endometrioid histotype.

Minerva Med 2020 Apr;111(2):133-140

Unit of Gynecologic Oncology, S. Orsola-Malpighi Polyclinic, University of Bologna, Bologna, Italy.

Background: The serum marker CA 125 is still the most widely used biomarker for ovarian cancer (OC) diagnosis in gynecological and oncological setting, but its predictive role in early-stage OC is still debated. The aim of this study was to explore the value of CA 125 in distinguishing between early-stage OC and borderline ovarian tumor (BOT) and to evaluate the accuracy of CA 125 in the detection of early stage OC.

Methods: A retrospective cohort study was performed at the University Hospital of Bologna (Italy) on 1296 consecutive women suffering from OC or BOT (diagnosed at histology) between 1988-2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.23736/S0026-4806.20.06474-5DOI Listing

Comparison of the predictive performance of risk of malignancy indexes 1-4, HE4 and risk of malignancy algorithm in the triage of adnexal masses.

J Ovarian Res 2020 Apr 25;13(1):46. Epub 2020 Apr 25.

Department of Obstetrics and Gynecology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450002, P. R. China.

Objectives: For patients presenting with adnexal mass, it is important to correctly distinguish whether the mass is benign or malignant for the purpose of precise and timely referral and implication of correct line of management. The objective of this study was to evaluate the performance of Risk of malignancy Indexes (RMI) 1-4, Human Epididymis Protein 4 (HE4) and Risk of Malignancy Algorithm (ROMA) in differentiating the adnexal mass into benign and malignant.

Methods: A retrospective study using 155 patients diagnosed with adnexal mass between January 2014 to December 2014 in The First Affiliated Hospital of Zhengzhou University was conducted. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13048-020-00643-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7183707PMC

A phase II, randomized study of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study.

J Gynecol Oncol 2020 May;31(3):e61

Ovarian Cancer Program, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Zhongshan Hospital, Fudan University, Shanghai, China.

Background: In China, secondary cytoreductive surgery (SCR) has been widely used in ovarian cancer (OC) over the past two decades. Although Gynecologic Oncology Group-0213 trial did not show its overall survival benefit in first relapsed patients, the questions on patient selection and effect of subsequent targeting therapy are still open. The preliminary data from our pre-SOC1 phase II study showed that selected patients with second relapse who never received SCR at recurrence may still benefit from surgery. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3802/jgo.2020.31.e61DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7189080PMC
May 2020
1.600 Impact Factor

Significance of lymph node ratio on survival of women with borderline ovarian tumors.

Arch Gynecol Obstet 2020 May 17;301(5):1289-1298. Epub 2020 Apr 17.

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, 2020 Zonal Avenue, IRD 520, Los Angeles, CA, 90033, USA.

Purpose: To assess the qualitative and quantitative measures of the effect of pelvic lymph node involvement on survival of women with borderline ovarian tumors (BOTs).

Methods: This is a retrospective study examining the Surveillance, Epidemiology, and End Results Program between 1988 and 2003. Women with stage T1-3 BOTs who had results of pelvic lymph node status at surgery were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00404-020-05535-0DOI Listing

Multigene Panel Germline Testing of 1333 Czech Patients with Ovarian Cancer.

Cancers (Basel) 2020 Apr 13;12(4). Epub 2020 Apr 13.

Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, 128 53 Prague, Czech Republic.

Ovarian cancer (OC) is the deadliest gynecologic malignancy with a substantial proportion of hereditary cases and a frequent association with breast cancer (BC). Genetic testing facilitates treatment and preventive strategies reducing OC mortality in mutation carriers. However, the prevalence of germline mutations varies among populations and many rarely mutated OC predisposition genes remain to be identified. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers12040956DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226062PMC

Nicotinamide N-methyltransferase overexpression may be associated with poor prognosis in ovarian cancer.

J Obstet Gynaecol 2020 Apr 14:1-6. Epub 2020 Apr 14.

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Selcuk University Medical School, Konya, Turkey.

Ovarian cancer is the fifth leading cause of cancer-related mortality in women. Nicotinamide N-methyltransferase (NNMT) is a metabolic enzyme and there is growing evidence to suggest that it plays an important role in cancer progression. This is the first study to examine the expression of NNMT in serous ovarian cystadenomas, serous borderline tumours, low grade serous carcinomas (LGSC) and high grade serous carcinomas (HGSC) and investigate the potential independent association of NNMT expression with survival. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/01443615.2020.1732891DOI Listing

Perfusion-based functional magnetic resonance imaging for differentiating serous borderline ovarian tumors from early serous ovarian cancers in a rat model.

Acta Radiol 2020 Apr 10:284185120913711. Epub 2020 Apr 10.

Department of Radiology, Jinshan Hospital, Shanghai Medical College, Fudan University, Shanghai, PR China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0284185120913711DOI Listing
April 2020
1.350 Impact Factor

Expression of EZH2 and P53 and their correlation in ovarian cancer tissues.

Int J Clin Exp Pathol 2020 1;13(3):456-464. Epub 2020 Mar 1.

Department of Clinical Laboratory, Cancer Hospital of Yunnan Province, The Third Affiliated Hospital of Kunming Medical University Kunming, Yunnan, China.

Previous researches have demonstrated that EZH2 expression is increased in many solid tumors and is closely related to the worse progression, transcriptional silence, distal metastasis, and differential inhibition of tumors. P53 can regulate many cells signaling pathways and play an important role in cell cycle, cell apoptosis, and cell senescence. However, there are few reports on the expression of EZH2 and p53 in ovarian cancer and their correlation with the ovarian cancer. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7137013PMC

Gynecologic cancer in pregnancy.

Gynecol Oncol 2020 Apr 5. Epub 2020 Apr 5.

Division of Gynecologic Oncology, University of California, Irvine Medical Center, Orange, CA, USA. Electronic address:

Cancer complicates 1 in 1000 pregnancies. Multidisciplinary consensus comprised of Gynecologic Oncology, Pathology, Neonatology, Radiology, Anesthesiology, Maternal Fetal Medicine, and Social Work should be convened. Pregnancy provides an opportunity for cervical cancer screening, with deliberate delays in treatment permissible for early stage carcinoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2020.03.015DOI Listing

Semaphorin-4C is upregulated in epithelial ovarian cancer.

Oncol Lett 2020 Apr 3;19(4):3333-3338. Epub 2020 Mar 3.

Department of Obstetrics and Gynecology, Dongying People's Hospital, Dongying, Shandong 257091, P.R. China.

The present retrospective study aimed to investigate the expression of semaphorin-4C (Sema4C) in epithelial ovarian cancer (EOC), and to determine the association between Sema4C expression and patient clinicopathological characteristics. Sema4C mRNA expression was detected by reverse transcription-quantitative polymerase chain reaction in the tissues of 74 cases of EOC, 20 cases of ovarian epithelial benign tumor, 20 cases of ovarian borderline epithelial tumor and 15 cases of normal ovarian tissue. Immunohistochemistry was used to detect the expression and localization of Sema4C. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/ol.2020.11444DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7074172PMC

Fertility and prognosis of borderline ovarian tumor after conservative management: Results of the multicentric OPTIBOT study by the GINECO & TMRG group.

Gynecol Oncol 2020 Apr;157(1):29-35

Institut Curie, St Cloud, France; Inserm U900, Institut Curie, St Cloud, France. Electronic address:

Objectives: Description of fertility and prognosis of patients with borderline ovarian tumor (BOT) treated by fertility-sparing surgery through a longitudinal study from the French national cancer network.

Methods: All consecutive patients diagnosed with BOT from the French National Network dedicated to Ovarian Malignant Rare Tumors from 2010 and 2017 were selected. In 2018, an update was made by sending a questionnaire regarding recurrence and fertility to patients aged under 43 years at diagnosis and treated conservatively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.12.046DOI Listing
April 2020
3.774 Impact Factor

Cancers associated with extraovarian endometriosis at less common/rare sites: A nationwide survey in Japan.

J Obstet Gynaecol Res 2020 Jun 25;46(6):917-923. Epub 2020 Mar 25.

Department of Obstetrics and Gynecology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.

Aim: Endometriosis mostly affects the ovary but can also be present outside of the ovary including the pelvic peritoneum, intestine, urinary tract and lung. In case of ovarian endometriotic cyst, an increased risk of ovarian cancer, especially of clear cell and endometrioid histology, has been reported. However, because of the rarity, cancer occurrence from endometriosis at less common sites/rare sites is poorly understood. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jog.14244DOI Listing

Upregulation of cyclase-associated actin cytoskeleton regulatory protein 2 in epithelial ovarian cancer correlates with aggressive histologic types and worse outcomes.

Jpn J Clin Oncol 2020 Mar 24. Epub 2020 Mar 24.

Department of Pathology, Keio University School of Medicine, Tokyo, Japan.

Objective: Cyclase-associated actin cytoskeleton regulatory protein 2 (CAP2) regulates actin dynamics to control cell cycles and cell migration. CAP2 overexpression contributes to cancer progression in several tumor types; however, the role of CAP2 expression in ovarian cancer remains unclear. This study aimed to clarify the significance of CAP2 expression in epithelial ovarian tumor. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jjco/hyaa026DOI Listing

Circulating cell-free DNA variables as marker of ovarian cancer patients: A pilot study.

Cancer Biomark 2020 Mar 6. Epub 2020 Mar 6.

Division of Molecular Epidemiology, German Cancer Research Center, Heidelberg, Germany.

Background: Minimal invasive blood-based molecular markers are evaluated as promising biomarkers in malignant diseases these days.

Objective: In this pilot study, we investigated the potential of cell-free DNA (cfDNA) concentration and cell-free DNA Integrity (cfDI) as blood-based diagnostic markers for ovarian cancer patients in a retrospective study cohort.

Methods: cfDNA concentration and cfDI were determined in the plasma of 37 ovarian cancer patients and 28 healthy controls, by measuring ALU and LINE1 repetitive DNA elements using quantitative real-time PCR. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/CBM-191018DOI Listing

Ultrasound Features Improve Diagnostic Performance of Ovarian Cancer Predictors in Distinguishing Benign and Malignant Ovarian Tumors.

Curr Med Sci 2020 Feb 13;40(1):184-191. Epub 2020 Mar 13.

Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.

To determine whether ultrasound features can improve the diagnostic performance of tumor markers in distinguishing ovarian tumors, we enrolled 719 patients diagnosed as having ovarian tumors at Nanfang Hospital from September 2014 to November 2016. Age, menopausal status, histopathology, the International Federation of Gynecology and Obstetrics (FIGO) stages, tumor biomarker levels, and detailed ultrasound reports of patients were collected. The area under the curve (AUC), sensitivity, and specificity of the bellow-mentioned predictors were analyzed using the receiver operating characteristic curve. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11596-020-2163-7DOI Listing
February 2020

Differentiation of borderline tumors from type I ovarian epithelial cancers on CT and MR imaging.

Abdom Radiol (NY) 2020 Mar 11. Epub 2020 Mar 11.

Department of Radiology, Shanghai Tenth People's Hospital of Tongji University, School of Medicine, Shanghai, 200072, China.

Purpose: To investigate the value of CT and MR imaging features in differentiating borderline ovarian tumor (BOT) from type I ovarian epithelial cancer (OEC), which could be significant for suitable clinical treatment and assessment of the prognosis of the patient.

Methods: Thirty-three patients with BOTs and 35 patients with type I OECs proven by pathology were retrospectively evaluated. The clinico-pathological information (age, premenopausal status, CA-125, and Ki-67) and imaging characteristics were compared between two groups of ovarian tumors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00261-020-02467-wDOI Listing

KNDC1 Is a Predictive Marker of Malignant Transformation in Borderline Ovarian Tumors.

Onco Targets Ther 2020 23;13:709-718. Epub 2020 Jan 23.

Department of Gynecology, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310051, People's Republic of China.

Background: Few screening markers for malignant transformation in borderline ovarian tumors (BOT) have been clearly established. The kinase noncatalytic C-lobe domain containing 1 (KNDC1), a brain-specific Ras guanine nucleotide exchange factor, negatively regulates dendrite growth. However, the biological role and underlying mechanism of KNDC1 in human cancers, including ovarian cancer (OC), remain unknown. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S223304DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6986543PMC
January 2020

The ADNEX model to triage adnexal masses: An external validation study and comparison with the IOTA two-step strategy and subjective assessment by an experienced ultrasound operator.

Eur J Obstet Gynecol Reprod Biol 2020 Apr 14;247:207-211. Epub 2020 Feb 14.

Department of Surgical Sciences, University of Turin -Turin, Italy.

Objectives: The ADNEX (Assessment of Different NEoplasias in the adneXa) model was developed using parameters collected by experienced (level III) ultrasound examiners. Our primary aim was to externally validate the ADNEX model. Then, the discriminatory performance of ADNEX was compared with the two-step strategy and subjective assessment by an experienced ultrasound operator. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejogrb.2020.02.022DOI Listing

Metastatic serous borderline tumor with micro-invasive ovarian carcinoma presenting as a breast lump: A case report.

Medicine (Baltimore) 2020 Feb;99(9):e19383

Department of Breast Surgery.

Rationale: Breast metastasis from serous borderline tumor with micro-invasive carcinoma of ovary is a very rare condition. The breast lump as the only clinical presentation is rarely seen in ovarian carcinoma, which may lead to be misdiagnosed, and the mechanism of breast metastasis from ovarian tumors in early stage still needs to be explored. Differentiation from primary breast cancer and extramammary malignancy is crucial because the treatment and prognosis are significantly different. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000019383DOI Listing
February 2020

Implication of IL-17 producing ɑβT and γδT cells in patients with ovarian cancer.

Hum Immunol 2020 May 21;81(5):244-248. Epub 2020 Feb 21.

Department of Gynecological Oncology, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University, 210029 Nanjing, China. Electronic address:

Objective: To investigate the expression and cellular source of IL-17A in human ovarian cancer (OC), benign ovarian tumor (BOT) and borderline ovarian tumor (OBT).

Methods: RT-PCR and immunohistochemistry were used to measure the expression level of IL-17A in human OC tissues. Find concrete source of the elevated IL-17A levels in OC tissues by flow cytometry. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.humimm.2020.02.002DOI Listing

Role of Frozen Section in Surgical Management of Ovarian Neoplasm.

Gynecol Minim Invasive Ther 2020 Jan-Mar;9(1):13-17. Epub 2020 Jan 23.

Department of Pathology, MES Medical College, Malappuram, Kerala, India.

Objective: Cancers of the adnexae, including ovarian and fallopian tube, constitute the eighth most common cancers among women worldwide. Surgery remains the cornerstone in the management of ovarian cancer. Intraoperative frozen section diagnosis of ovarian tumors is widely used in making this distinction and to decide the course of surgery. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/GMIT.GMIT_2_19DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7008647PMC
January 2020

Mucinous borderline ovarian tumors with and without Intraepithelial Carcinoma: Differences in clinicopathologic features and fertility results.

J Obstet Gynaecol Res 2020 Apr 11;46(4):646-653. Epub 2020 Feb 11.

Department of Gynecological Oncology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, People's Republic of China.

Aim: To investigate the clinicopathologic characteristic and fertility results of patients with mucinous borderline ovarian tumors (MBOTs), and the effects of intraepithelial carcinoma (IECA) on them.

Methods: Fifty-two patients treated for MBOTs with or without IECA were retrospectively analyzed.

Results: Patients with IECA were more frequently observed at stage Ic (3/12 vs 1/40, P = 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jog.14210DOI Listing
April 2020
0.931 Impact Factor

MRI-Based Machine Learning for Differentiating Borderline From Malignant Epithelial Ovarian Tumors: A Multicenter Study.

J Magn Reson Imaging 2020 Feb 11. Epub 2020 Feb 11.

Suzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Sciences, Suzhou, China.

Background: Preoperative differentiation of borderline from malignant epithelial ovarian tumors (BEOT from MEOT) can impact surgical management. MRI has improved this assessment but subjective interpretation by radiologists may lead to inconsistent results.

Purpose: To develop and validate an objective MRI-based machine-learning (ML) assessment model for differentiating BEOT from MEOT, and compare the performance against radiologists' interpretation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jmri.27084DOI Listing
February 2020

Association between pelvic inflammatory disease and risk of ovarian cancer: An updated meta-analysis.

Gynecol Oncol 2020 May 7;157(2):542-548. Epub 2020 Feb 7.

Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Republic of Korea; Department of Obstetrics and Gynecology, Seoul National University Hospital, Seoul, Republic of Korea. Electronic address:

Background: Because of conflicting reports regarding the relationship between pelvic inflammatory disease (PID) and ovarian cancer, we performed an updated meta-analysis to investigate the association between PID and the risk of this malignancy.

Methods: Embase, PubMed, and Web of Science were searched up until November 1, 2019. Hazard ratios (HRs), along with 95% confidence intervals (CIs), were calculated to analyse outcomes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2020.02.002DOI Listing

Ovarian Seromucinous Tumors: Pathogenesis, Morphologic Spectrum, and Clinical Issues.

Diagnostics (Basel) 2020 Jan 31;10(2). Epub 2020 Jan 31.

Department of Diagnostic Pathology, Kumamoto University Hospital, Japan.

Ovarian seromucinous tumors were introduced in the 2014 World Health Organization (WHO) classification as one of the seven types of ovarian epithelial tumors. They are characterized by frequent association with endometriosis and bilaterality, microscopic appearance of papillary architecture, and admixture of a variety of müllerian-type epithelium. They are considered to be endometriosis-related ovarian neoplasms, along with endometrioid and clear cell tumors; recent molecular studies suggest this particular tumor is a variant of endometrioid tumor. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/diagnostics10020077DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7168900PMC
January 2020

[Borderline Ovarian Tumours: CNGOF guidelines for Clinical Practice - Methods & Organization].

Gynecol Obstet Fertil Senol 2020 03 28;48(3):236-238. Epub 2020 Jan 28.

Service de gynécologie-obstétrique et médecine de la reproduction, institut universitaire de cancérologie (IUC), centre Cancer Associé à La Grossesse (CALG), hôpital Tenon, UMR938, faculté de médecine UPMC, Sorbonne université, Assistance publique-Hôpitaux de Paris (AP-HP), Paris, France.

This text presents organizational and methodological aspects of the development of the French guidelines on the management of borderline ovarian tumours. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.gofs.2020.01.023DOI Listing

[Borderline Ovarian Tumours: CNGOF Guidelines for Clinical Practice - Value of Tumor Markers].

Gynecol Obstet Fertil Senol 2020 03 28;48(3):277-286. Epub 2020 Jan 28.

Département de gynécologie-obstétrique et reproduction humaine, 16, boulevard de Bulgarie, 35000 Rennes, France; UFR médecine université de Rennes 1, CHU Anne-de-Bretagne, Bretagne, France. Electronic address:

Objectives: To evaluate the diagnostic value of serum biomarkers in the management strategy of borderline ovarian tumours (BOT) to make management recommendations.

Methods: English and French review of literature from 1990 to 2019 based on publications from Pubmed, Medline, Cochrane, with keywords: borderline ovarian tumors, tumour markers, CA125, CA19 9, ACE, CA72 4, TAG72, HE4, ROMA, mucinous, serous, mucinous, endometrioid ovarian tumours, peritoneal implants, recurrence, overall survival, follow-up. Among 1000 references, 400 were selected and only 30 were screened for this work. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.gofs.2020.01.015DOI Listing

[Borderline Ovarian Tumours: CNGOF Guidelines for Clinical Practice - Therapeutic Management of Early Stages].

Gynecol Obstet Fertil Senol 2020 03 28;48(3):287-303. Epub 2020 Jan 28.

Service de chirurgie et oncologie gynécologique et mammaire, AP-HP, hôpital Pitié-Salpêtrière, 75013 Paris, France; Biologie et thérapeutique du cancer, centre de recherche Saint-Antoine (CRSA), Sorbonne université, 75012 Paris, France.

Objectives: To provide guidelines for clinical practice from the French College of Obstetrics and Gynecology (CNGOF), based on the best evidence available, concerning early stage borderline ovarian tumors (BOT).

Methods: Bibliographical search in French and English languages by consultation of Pubmed, Cochrane, Embase, and international databases.

Results: Considering management of early stage BOT, if surgery is possible without a risk of tumor rupture, the laparoscopic approach is recommended compared to laparotomy (Grade C). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.gofs.2020.01.016DOI Listing

[Borderline Ovarian Tumours: CNGOF Guidelines for Clinical Practice - Surgical Management of Advanced Stages of Borderline Ovarian Tumours].

Authors:
E Raimond N Bourdel

Gynecol Obstet Fertil Senol 2020 03 28;48(3):304-313. Epub 2020 Jan 28.

Département de chirurgie gynécologique, CHU d'Estaing, 1, rue Lucie-et-Raymond-Aubrac, 63003 Clermont-Ferrand, France.

Objective: To evaluate the surgical management of borderline ovarian tumors (BOT) in the framework of recommendations for clinical practice made by the National College of Obstetricians and Gynecologists (CNGOF) METHODS: This is a comprehensive review of the literature on the advanced stages of BOT. Bibliographic selection was conducted in PubMed from 2007 to 2019 inclusive, selecting publications in English and French. Articles were selected on the basis of the title, then the abstract and finally the full article. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.gofs.2020.01.017DOI Listing

[Borderline Ovarian Tumours: CNGOF Guidelines for Clinical Practice - Fertility].

Gynecol Obstet Fertil Senol 2020 03 28;48(3):330-336. Epub 2020 Jan 28.

Service de gynécologie-obstétrique et médecine de la reproduction, hôpital Tenon, Assistance publique-Hôpitaux de Paris, 4, rue de la Chine, 75020 Paris, France; UMR_S938 université Pierre-et-Marie-Curie, Paris 6, institut universitaire de cancérologie (IUC), Paris, France.

Objectives: Borderline ovarian tumours (BOT) represent around 15% of all ovarian neoplasms and are more likely to be diagnosed in women of reproductive age. Overall, given the epidemiological profile of BOT and their favourable prognosis, ovarian function and fertility preservation should be systematically considered in patients presenting these lesions.

Methods: The research strategy was based on the following terms: borderline ovarian tumour, fertility, fertility preservation, infertility, fertility-sparing surgery, in vitro fertilization, ovarian stimulation, oocyte cryopreservation, using PubMed, in English and French. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.gofs.2020.01.020DOI Listing

[Borderline Ovarian Tumours: CNGOF Guidelines for Clinical Practice - Short Text].

Gynecol Obstet Fertil Senol 2020 03 28;48(3):223-235. Epub 2020 Jan 28.

Service de gynécologie-obstétrique et médecine de la reproduction, hôpital Tenon, Centre CALG (Cancer Associé à La Grossesse), Institut universitaire de cancérologie (IUC), UMRS-938, faculté de médecine UPMC, Sorbonne université, Assistance publique-Hôpitaux de Paris (AP-HP), France; Faculté de médecine UPMC, Sorbonne université, Paris, France.

This work was carried out under the aegis of the CNGOF (Collège national des gynécologues et obstétriciens français) and proposes guidelines based on the evidence available in the literature. The objective was to define the diagnostic and surgical management strategy, the fertility preservation and surveillance strategy in Borderline Ovarian Tumor (BOT). No screening modality can be proposed in the general population. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.gofs.2020.01.022DOI Listing

Association between pelvic inflammatory disease, infertility, ectopic pregnancy and the development of ovarian serous borderline tumor, mucinous borderline tumor and low-grade serous carcinoma.

Gynecol Oncol 2020 Mar 23;156(3):611-615. Epub 2020 Jan 23.

School of Public Health, The University of Queensland, Brisbane, Australia; Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Australia.

Objective: Risk factors for ovarian borderline tumors and low-grade serous carcinoma (LGSC) are poorly understood. The aim of this study was to examine the association between infertility, pelvic inflammatory disease (PID), endometriosis, ectopic pregnancy, hysterectomy, tubal ligation and parity and the risk of serous borderline tumor (SBT), mucinous borderline tumor (MBT) and LGSC.

Methods: This was a population-based cohort study using linked administrative and hospital data. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2020.01.027DOI Listing

Clinical and pathological features of women with adnexal masses admitted as emergency cases to the Gynaecology Department of West Kazakhstan University.

Prz Menopauzalny 2019 Dec 4;18(3):180-183. Epub 2019 Dec 4.

Department of Normal and Topographical Anatomy, West Kazakhstan Marat Ospanov Medical University, Aktobe, Kazakhstan.

Aim Of The Study: To detect the clinical and pathological features of women with adnexal masses (AMs) admitted as emergency cases to the Gynaecology Department of West Kazakhstan University.

Material And Methods: A retrospective analysis of the data of women with AMs admitted as an emergency cases to the Gynaecology Department of West Kazakhstan University. The collected data include: age, age of menarche and age of menopause, presenting symptoms, admission criteria - either self-referral or refereed from another department, ultrasound findings, associated pregnancy, associated pathology of the female genital tract, and post-operative histological results of surgically excised AMs (gold standard). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5114/pm.2019.90377DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6970418PMC
December 2019
0.381 Impact Factor

Evaluation of adnexal tumours in the International Ovarian Tumor Analysis system in reference to histopathological results.

Prz Menopauzalny 2019 Dec 20;18(3):141-145. Epub 2019 Dec 20.

1 Department of Gynaecology and Obstetrics, Clinic of Surgical and Oncological Gynecology, M. Pirogow's Teaching Hospital, Medical University of Lodz, Lodz, Poland.

Aim Of The Study: To retrospectively evaluate how the International Ovarian Tumor Analysis (IOTA) simple rules used in ultrasound examinations estimate the probability of malignant and benign tumour occurrence in the studied population.

Material And Methods: The study was performed on a group of 425 patients with ovarian tumours operated in the Clinic of Surgical and Oncological Gynecology at the Medical University of Lodz in the years 2014-2015. Adnexal tumours were rated according to IOTA simple rules, classifying them as probably malignant, probably benign, or unclassified. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5114/pm.2019.90812DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6970421PMC
December 2019

A Prospective Analysis of Circulating Plasma Metabolites Associated with Ovarian Cancer Risk.

Cancer Res 2020 Mar 22;80(6):1357-1367. Epub 2020 Jan 22.

Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.

Ovarian cancer has few known risk factors, hampering identification of high-risk women. We assessed the association of prediagnostic plasma metabolites ( = 420) with risk of epithelial ovarian cancer, including both borderline and invasive tumors. A total of 252 cases and 252 matched controls from the Nurses' Health Studies were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-19-2567DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7073287PMC

Low-grade serous ovarian cancer: State of the science.

Gynecol Oncol 2020 Mar 20;156(3):715-725. Epub 2020 Jan 20.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

In January 2019, a group of basic, translational, and clinical investigators and patient advocates assembled in Miami, Florida, to discuss the current state of the science of low-grade serous carcinoma of the ovary or peritoneum-a rare ovarian cancer subtype that may arise de novo or following a diagnosis of serous borderline tumor. The purpose of the conference was to review current knowledge, discuss ongoing research by established researchers, and frame critical questions or issues for future directions. Following presentations and discussions, the primary objective was to initiate future collaborations, uniform database platforms, laboratory studies, and clinical trials to better understand this disease and to advance clinical care outside the boundaries of single academic institutions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.12.033DOI Listing

Diagnosis-shift between low-grade serous ovarian cancer and serous borderline ovarian tumor: A population-based study.

Gynecol Oncol 2020 Apr 15;157(1):21-28. Epub 2020 Jan 15.

Department of Gynecologic Oncology & Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Objective: To determine changes in the characteristics of low-grade serous ovarian cancer (LGSOC) and serous borderline ovarian tumor (serous-BOT) in a time-specific manner.

Methods: We conducted a population-based retrospective study examining the Surveillance, Epidemiology, and End Results Program from 1988 to 2000. Trends, demographics, and outcomes of 775 women with well-differentiated serous ovarian cancer, used as a surrogate for LGSOC, were compared to 3937 women with serous-BOT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.08.030DOI Listing

Neurofibromin 1 expression is negatively correlated with malignancy and prognosis of epithelial ovarian cancer.

Int J Clin Exp Pathol 2019 1;12(5):1702-1712. Epub 2019 May 1.

Department of Obstetrics and Gynecology, Xijing Hospital, Fourth Military Medical University Xi'an, Shaanxi, China.

Epithelial ovarian cancer ranks as the 5 most deadly female cancer. However, few effective biomarkers have been identified for clinical application. Thus, it is critical to identify differentially expressed genes in epithelial ovarian cancer patient samples. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6947127PMC

Association of Anti-Mullerian Hormone, Follicle-Stimulating Hormone, and Inhibin B with Risk of Ovarian Cancer in the Janus Serum Bank.

Cancer Epidemiol Biomarkers Prev 2020 Mar 13;29(3):636-642. Epub 2020 Jan 13.

Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland.

Background: Reproductive factors, including parity, breastfeeding, and contraceptive use, affect lifetime ovulatory cycles and cumulative exposure to gonadotropins and are associated with ovarian cancer. To understand the role of ovulation-regulating hormones in the etiology of ovarian cancer, we prospectively analyzed the association of anti-Mullerian hormone (AMH), follicle-stimulating hormone (FSH), and inhibin B with ovarian cancer risk.

Methods: Our study included 370 women from the Janus Serum Bank, including 54 type I and 82 type II invasive epithelial ovarian cancers, 49 borderline tumors, and 185 age-matched controls. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1055-9965.EPI-19-0675DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7060092PMC

Favorable prognostic impact of Natural Killer cells and T cells in high-grade serous ovarian carcinoma.

Acta Oncol 2020 Jun 14;59(6):652-659. Epub 2020 Jan 14.

Department of Oncology, University Hospital of Southern Denmark, Vejle, Denmark.

The aim of the present study was to investigate the prognostic impact of intratumoral cytotoxic T cells, Natural Killer (NK) cells, neutrophils and PD-L1 expression in patients with epithelial ovarian cancer. All patients diagnosed with high-grade serous carcinoma (HGSC) in Denmark in 2005 were included in the study. Immunohistochemical staining for PD-L1, CD8, CD66b and CD57 was performed on tumor tissue from 283 patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/0284186X.2019.1711173DOI Listing